UTHR UNITED THERAPEUTICS Corp

Price (delayed)

$336.74

Market cap

$14.94B

P/E Ratio

15.06

Dividend/share

N/A

EPS

$22.36

Enterprise value

$14.28B

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights
UNITED THERAPEUTICS's net income has increased by 44% YoY and by 7% QoQ
The company's EPS rose by 41% YoY and by 6% QoQ
The equity has declined by 11% since the previous quarter but it has increased by 4.2% year-on-year
The quick ratio has dropped by 62% year-on-year and by 14% since the previous quarter
The stock's P/E is 37% above its last 4 quarters average of 11.0 and 9% above its 5-year quarterly average of 13.8

Key stats

What are the main financial stats of UTHR
Market
Shares outstanding
44.36M
Market cap
$14.94B
Enterprise value
$14.28B
Valuations
Price to book (P/B)
2.97
Price to sales (P/S)
6.34
EV/EBIT
9.92
EV/EBITDA
9.56
EV/Sales
5.72
Earnings
Revenue
$2.5B
EBIT
$1.44B
EBITDA
$1.49B
Free cash flow
$752.4M
Per share
EPS
$22.36
Free cash flow per share
$16.01
Book value per share
$113.44
Revenue per share
$53.16
TBVPS
$135.74
Balance sheet
Total assets
$6.5B
Total liabilities
$1.16B
Debt
$600M
Equity
$5.34B
Working capital
$2.39B
Liquidity
Debt to equity
0.11
Current ratio
3.77
Quick ratio
3.5
Net debt/EBITDA
-0.44
Margins
EBITDA margin
59.8%
Gross margin
88.9%
Net margin
42%
Operating margin
50.3%
Efficiency
Return on assets
15.4%
Return on equity
18.7%
Return on invested capital
25.6%
Return on capital employed
25.6%
Return on sales
57.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
1.24%
1 week
2.61%
1 month
6.55%
1 year
35.65%
YTD
53.14%
QTD
5.71%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.5B
Gross profit
$2.22B
Operating income
$1.26B
Net income
$1.05B
Gross margin
88.9%
Net margin
42%
UNITED THERAPEUTICS's net income has increased by 44% YoY and by 7% QoQ
The operating income has grown by 29% YoY and by 6% from the previous quarter
The company's revenue rose by 26% YoY and by 7% QoQ
The company's gross profit rose by 23% YoY and by 7% QoQ

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
P/E
15.06
P/B
2.97
P/S
6.34
EV/EBIT
9.92
EV/EBITDA
9.56
EV/Sales
5.72
The company's EPS rose by 41% YoY and by 6% QoQ
The stock's P/E is 37% above its last 4 quarters average of 11.0 and 9% above its 5-year quarterly average of 13.8
UTHR's price to book (P/B) is 56% higher than its 5-year quarterly average of 1.9 and 56% higher than its last 4 quarters average of 1.9
The equity has declined by 11% since the previous quarter but it has increased by 4.2% year-on-year
The stock's P/S is 41% above its 5-year quarterly average of 4.5 and 38% above its last 4 quarters average of 4.6
The company's revenue rose by 26% YoY and by 7% QoQ

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 41% YoY and by 12% from the previous quarter
UNITED THERAPEUTICS's return on assets has increased by 25% YoY and by 6% QoQ
The ROE has grown by 21% YoY and by 6% from the previous quarter
The company's return on sales rose by 17% YoY

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The current ratio has plunged by 62% YoY and by 15% from the previous quarter
The quick ratio has dropped by 62% year-on-year and by 14% since the previous quarter
The debt is 89% less than the equity
UNITED THERAPEUTICS's debt to equity has decreased by 31% YoY and by 8% QoQ
The debt has contracted by 25% YoY and by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.